Eribulin Mesylate is an antitumor drug that can be used to treat patients with metastatic breast cancer. It inhibits the proliferation of cancer cells by binding tubulin and microtubules. Eribulin Mesylate can inhibit experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Structure of 441045-17-6
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
1 mg | $1099 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
NCT Number | Title | Condition Or Disease | Phase | Start Date | Sponsor | Status |
---|---|---|---|---|---|---|
NCT00047034 | E7389 in Treating Patients With Advanced Solid Tumors | Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | August 2002 | National Cancer Institute (NCI) | Completed |
NCT00334893 | Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | Fallopian Tube Cancer | Phase 2 | April 2006 | National Cancer Institute (NCI) | Completed |
NCT00337077 | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | Adenocarcinoma of the Prostate | Phase 2 | November 2006 | National Cancer Institute (NCI) | Completed |
NCT00337103 | E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | Metastatic Breast Cancer | Phase 3 | June 15, 2006 | Eisai Inc. | Completed |
NCT00337129 | S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | Head and Neck Cancer | Phase 2 | May 2006 | National Cancer Institute (NCI) | Completed |
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00660 | VCP-Eribulin | 2130869-17-7 | |
BADC-00860 | Mal-PEG2-VCP-Eribulin | 2130869-18-8 | |
BADC-01611 | Farletuzumab ecteribulin | 2407465-18-1 | |
BADC-01379 | Eribulin | 253128-41-5 |
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.